501derful.org

In the previous installment about the molecular medicine conference, I emphasized that the science of so-called complex, polygenic diseases like cancer is, well, complex. But there are other complications as well in the life science business. Biotechnology and pharmaceuticals are also risky, complicated enterprises from a financial standpoint. In a way it’s kind of a layering of complexities, one atop ...

From a Voluntary Health Association perspective Social Software is an umbrella term for a series of business solutions that are focused on inter connecting and facilitating the organization of people. Much of what is being developed is not in it self-new. It is a new way of looking at and doing things. In fact many of the application are variants ...

I had the good fortune to attend (thanks to FI Center) the “Molecular Medicine Tri-Conference” in San Francisco last week. The attendees were researchers, executives of biotech and pharmaceutical companies, a few scientists from NCI or NIH, and me—as far as I can tell, the single NGO nonprofit person. (That’s not to say all the companies present are turning a ...

Just a quick update for those of you helping to fund this project. On 3/18 I met with NHO staff from Health Initiatives and Direct Channels as well as the Futuring and Innovation Center and re-named the CA-Tools 2.0 to the C-Tools 2.0. This will be the new name of the program going forth. On 3/22 we determined that due ...